News & Media

Media Inquiries & Public Relations

We welcome media inquiries and can connect you with the leading pancreatic cancer researchers, physicians, patients and caregivers.

Erin Stoeber, VP, Marketing & Communications

Office: 516.737-1557
Cell: 646-327-3746
estoeber@lustgarten.org

Vanessa Steil, Social Media & PR Manager

Office: 516.737.1566
Cell: 631.334.4587
vsteil@lustgarten.org

Press Releases

2018 Press Releases


Lustgarten Funded Study Shows Loss of Fat and Muscle is a Common First Sign of Pancreatic Cancer

Woodbury, N.Y., June 21, 2018 – In a study published in Nature, researchers found that the breakdown of muscle tissue and adipose (fat) is an early sign of pancreatic cancer. The Lustgarten-funded research was conducted by Dr. Laura Danai and Dr. Matthew Vander Heiden from Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, and Dr. Ana Babic and Dr. Brian Wolpin at Dana-Farber Cancer Institute. These promising findings may contribute to earlier detection of pancreatic cancer. Read More…

Organoids Accurately Predict Treatment Response of Pancreatic Cancer Patients

Woodbury, NY (May 31, 2018) – Today in Cancer Discovery, an international team of researchers led by Dr. David Tuveson, Cold Spring Harbor Laboratory (CSHL) Professor and Chief Scientist of the Lustgarten Foundation, reports on results of 66 organoids derived from pancreatic ductal adenocarcinoma (PDAC) tumor specimens at various stages of the disease. The researchers demonstrated that the patient-derived organoids, which are three-dimensional hollow spheres of cells cultured from tumors, can quickly and accurately predict how patients with pancreatic cancer respond to a variety of treatments, facilitating a personalized medicine approach to the deadly disease. Read More…

Lustgarten-Funded Researcher Unlocks How Pancreatic Cancer Metastasizes to the Liver

WOODBURY, N.Y., May 17, 2018 /PRNewswire-USNewswire/ — Lustgarten Foundation Distinguished Scholar Douglas Fearon, M.D., a professor at Cold Spring Harbor Laboratory (CSHL), has discovered how pancreatic cancer metastasizes to the liver following surgery, as reported in today’s online edition of leading biomedical journal Science.”This discovery is significant because for patients who undergo pancreatic cancer surgery, there is typically a period lasting up to two weeks during which T cells are depleted, owing to a surge in post-operative stress hormone (cortisol) levels,” Dr. Fearon said.. Read More…

The Lustgarten Foundation and Stand Up To Cancer Launch Partnership Focused on Pancreatic Cancer

CHICAGO, April 16, 2018 /PRNewswire/ — The Lustgarten Foundation for Pancreatic Cancer Research and Stand Up To Cancer (SU2C) announced Sunday at the Annual Meeting of the American Association for Cancer Research that they are entering into a formal strategic partnership to drive research to improve outcomes for pancreatic cancer patients. The Pancreatic Cancer Collective will accelerate research for pancreatic cancer patients who desperately need better treatments. With support from the Lustgarten Foundation and Stand Up To Cancer, the Pancreatic Cancer Collective launches with an initial commitment of $25 million. Read More…

Announcing the Pancreatic Cancer Collective An initiative of the Lustgarten Foundation and Stand Up To Cancer


CHICAGO, April 15, 2018 /PRNewswire-USNewswire/ — The Lustgarten Foundation and Stand Up To Cancer (SU2C) announced today at the Annual Meeting of the American Association for Cancer Research, SU2C’s Scientific Partner, that they are entering into a formal strategic partnership to drive research to improve outcomes for pancreatic cancer patients. The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients who desperately need better treatments. The initial funding commitment will be $25 million. Read More…

Gavin DeGraw Lends His Voice To Pancreatic Cancer Research Partnering With The Lustgarten Foundation To Raise Awareness


WOODBURY, N.Y., March 28, 2018 /PRNewswire/ — Having lost his mother to the disease, singer, songwriter Gavin DeGraw knows firsthand how devastating pancreatic cancer is for patients and their families. Gavin is turning his grief into action by helping the Lustgarten Foundation raise awareness by encouraging people to get involved with the Foundation. Experience the interactive Multichannel News ReleaseRead More…

Lustgarten Foundation Appoints Two New Board Members

WOODBURY, N.Y., March 20, 2018 /PRNewswire-USNewswire/ — The Lustgarten Foundation announced today the appointment of two new board members – Dr. Kenneth Goodman and Ms. Willa Shalit – to its current 12-member Board of Directors. Dr. Goodman brings years of radiology and leadership experience to the role while Ms. Shalit has extensive expertise in both the for-profit and not-for-profit sectors and is the co-founder of Let’s Win, an affiliate organization of the Foundation.Read More…

LUSTGARTEN FOUNDATION APPOINTS DAVID TUVESON, M.D., Ph.D., CHIEF SCIENTIST

WOODBURY, New York (March 19, 2018) — The Lustgarten Foundation announced today the appointment of David Tuveson, M.D., Ph.D., as its Chief Scientist. Dr. Tuveson is the Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center, the Roy J. Zuckerberg Professor of Cancer Research and oversees the Lustgarten Foundation’s dedicated research laboratory at Cold Spring Harbor Laboratory. He previously served as the Foundation’s Research Director.Read More…

Stand Up To Cancer Announces $11M Collaborative, Multi-disciplinary Research Program; Microsoft Will Bring Power of AI to Investigate Immune System Response to Cancers

Santa Monica, CA (January 30, 2018) — Stand Up To Cancer (SU2C) announces today a “Convergence 2.0” research initiative that awards $11 million to seven multi-disciplinary research teams to investigate immune system response to cancers. The multi-institutional teams being announced today at SU2C’s Scientific Summit draw from the nation’s top academic research centers and will have access to Microsoft Research’s experts in machine learning and artificial intelligence.Read More…

Study Shows Blood Test Can Detect 8 Types of Cancer


WOODBURY, N.Y., Jan. 18, 2018 /PRNewswire/ — Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. Read More…

Lustgarten Foundation Awarded $22 Million For Pancreatic Cancer Research


WOODBURY, N.Y., Jan. 15, 2018 /PRNewswire-USNewswire/ — The Lustgarten Foundation announced today that it funded $22 million in 2017 as part of its commitment to invest an unprecedented $40 million by the end of 2018. In addition to funding the most accomplished scientists in pancreatic cancer research, the Foundation is attracting new researchers to the field. New to the field of pancreatic cancer research as a result of this funding are David Sabatini, M.D., Ph.D., Whitehead Institute for Biomedical Research and David Pellman, M.D., Dana-Farber Cancer Institute. Read More…

CREATIVE BATH PRODUCTS, INC. DONATES $3.9 MILLION TO THE LUSTGARTEN FOUNDATION FOR PC RESEARCH


WOODBURY, New York (Jan 10, 2018) – The Lustgarten Foundation announced today that it received nearly $4 million from Creative Bath Products, Inc. to support pancreatic cancer research. The Central Islip headquartered Creative Bath Products consists of five business units: Creative Bath Products, Inc.,Creative Ware, Creative Home Furnishings, Creative Private Label/U.S. Manufacturing and Bath Creations. The Lustgarten Foundation is the largest private funder of pancreatic cancer research. Thanks to private funding, 100 percent of every dollar donated by Creative Bath Products will go directly to research Read More…

2017 Press Releases

Lustgarten Foundation and Stand Up To Cancer Announce Two New Pancreatic Cancer Research Projects Focused on Doubling the Number of Surgical Interventions

Woodbury, NY (October 26, 2017) – The Lustgarten Foundation and Stand Up To Cancer (SU2C) announced today the launch of two new pancreatic cancer interception research projects – one focused on earlier detection and the other on surgical intervention. The total investment for these projects is nearly $10 million and will involve thousands of patients.“We are pleased to once again join forces with Stand Up To Cancer,” said Dr. Robert Vizza, the Foundation’s Vice Chairman, Research. “Since only 15% of pancreatic cancer patients are currently eligible for surgery, if we are able to diagnose patients earlier and increase the number of patients who can have surgery, we will significantly increase survival rates.”  Read More…

 

NEW STUDY SHOWS PROMISING RESULTS IN THE DEVELOPMENT OF MORE EFFECTIVE BLOOD TEST TO DETECT PANCREATIC CANCER

WOODBURY, NY, September 5, 2017 A study published the week of September 4th in Proceedings of the National Academy of Science shows how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity (64% of early stage patients detected) while retaining very high specificity or accuracy (99.5% or less than 1% false positive). The combination of ctDNA and protein markers was superior to any single marker alone. This work was funded in part by the Lustgarten Foundation which is the largest private funder of pancreatic cancer research. Read More…


Mechanism of metastasis is discovered in pancreatic cancer

WOODBURY, NY, July 27, 2017 – Lustgarten Foundation funded research discovered a mechanism of metastasis in pancreatic cancer, and perhaps, other cancer types as well. The Foundation’s dedicated lab at Cold Spring Harbor Laboratory (CSHL) used organoid technology to find that pancreatic cancer cells reprogram gene enhancers to achieve the ability to spread. The research, appearing online today in Cell, provides strong evidence supporting this explanation of metastasis, which is the cause of most cancer deaths. Experiments conducted by postdoctoral investigators of the Vakoc and Tuveson labs at CSHL, focused on cells of the pancreas since most pancreatic cancer cases culminate in metastasis.  Read More…


LUSTGARTEN FOUNDATION TO COMMIT $40 MILLION TO PANCREATIC CANCER RESEARCH IN 2017-18

Woodbury, N.Y., July 12, 2017 The Lustgarten Foundation announced today that it will commit an unprecedented $40 million in 2017-18 through its new Translational Clinical Program, expanded Research Investigator Award Program and other partnerships. This is the first time any pancreatic cancer organization will commit that level of funding in a condensed period of time. As part of the Foundation’s research strategy, it will fund significant research projects in the areas of earlier detection, personalized medicine and developing new therapeutics with improved drug delivery. Read More…


LUSTGARTEN FOUNDATION FUNDED RESEARCH FINDS T CELL PROXIMITY TO PANCREATIC CANCER CELLS CORRELATES WITH INCREASED PATIENT SURVIVAL

BETHPAGE, N.Y., May 1, 2017 Findings reinforce the importance of immunotherapy research. Lustgarten Foundation’s funded research found that spatial distribution of cytotoxic T-cells in proximity to pancreatic ductal adenocarcinoma (PDAC) cancer cells correlates with increased patient survival. Desmoplasia, the growth of fibrous or connective tissue, causes dense fibrosis around the tumor making it difficult to treat the cancer. It has been hypothesized that desmoplastic materials create an impenetrable environment and drive T lymphocytes away from cancer cells, which are necessary for the body’s immune response.  Read More…

 

Newly Discovered Mutations Impair Key Cell Pathways in Pancreatic Cancer

Cold Spring Harbor, NY — By closely studying a part of the human genome that has not yet been carefully scrutinized in studies of cancer, researchers at Cold Spring Harbor Laboratory (CSHL) have found important new clues to the development of pancreatic cancer.The researchers looked exclusively at small segments of DNA called promoters in samples of tumors taken from 308 pancreatic cancer patients. Promoters are typically located adjacent to genes that they have a role in regulating. An activated promoter can, for example, switch “on” the gene it sits next to. One of many causes of cancer are genes that stay “on” for too long, bypassing natural signals to shut down. This is one way cancers grow out of control. Read More…

2016 Press Releases


16TH ANNUAL HOLIDAY ROCK & ROLL BASH RAISES $1.2 MILLION FOR THE LUSTGARTEN FOUNDATION

BETHPAGE, NY, December 15, 2016 – On Wednesday evening, December 14, The Madison Square Garden Company (NYSE: MSG) and AMC Networks (NASDAQ: AMCX) hosted the 16th Annual Holiday Rock & Roll Bash to benefit the Lustgarten Foundation, the nation’s largest private nonprofit funder of pancreatic cancer research. The Bash is the Foundation’s premier fundraising event, and this year, raised $1.2 million. Due to the support of private funding, 100 percent of every dollar raised goes directly to pancreatic cancer research.  Read More…

Stand Up To Cancer Returns For Fifth Live Roadblock Telecast Friday, September 9th – Bradley Cooper to Executive Produce With Award-Winning Team at Done + Dusted

LOS ANGELES – JUNE 16, 2016 –The Hollywood community is once again uniting to support Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), which will stage its fifth biennial televised fundraising special on Friday, Sept. 9 (8:00 – 9:00 PM ET/PT / 7:00 PM CT). Academy Award-nominated actor and founder of the Charles J Cooper Patient Support Fund, Bradley Cooper, will serve as executive producer along with renowned live, large-scale event producers Done + Dusted, working with Stand Up To Cancer’s production team. Additional stars and performers will be announced in the coming weeks. Read More…

The Lustgarten Foundation Joins More Than 40 Global Pancreatic Cancer Organizations At Inaugural Meeting

World Pancreatic Cancer Coalition Aims to Raise Unprecedented Awareness for a Disease with the Lowest Survival Rate of Any Major Cancer
The first-ever World Pancreatic Cancer Coalition (WPCC) will gather for its inaugural meeting in Orlando, Fla., on May 11, 2016, bringing together more than 60 individuals representing 40 pancreatic cancer advocacy groups from around the globe. The Coalition’s goal is to drive transformational change for those affected by pancreatic cancer. Read More…

Progress & Promise Newsletter

Our bi-annual newsletter features research updates, inspirational stories and highlights some of the many community events hosted on our behalf. If you have a story idea for consideration, send it to us at info@lustgarten.org.

2016 – Fall 2016 – Winter  I  2017 – Fall  I  2017 – Winter 2018 – Spring

Join Our Email List

We always have news to share. Whether it’s communicating groundbreaking findings or information about an event, keep up-to-date with all of the happenings at the Foundation by joining our email list.